

MINUTES – *Open Session*

Regular Meeting of the

Santa Clara County Health Authority Pharmacy & Therapeutics Committee

Thursday, June 20, 2019, 6:00 PM - 8:00 PM

Santa Clara Family Health Plan, Redwood

6201 San Ignacio Ave, San Jose, CA 95119

Voting Committee Members	Specialty	Present (Y or N)
Jimmy Lin, MD, Chairperson	Internal Medicine	Y
Hoa Bui, BS, RPh	Community Pharmacy (Walgreens)	N
Minh Thai, MD	Family Practice	N
Amara Balakrishnan, MD	Pediatrics	Y
Peter Nguyen, MD	Family Practice	N
Jesse Parashar-Rokicki, MD	Family Practice	Y
Narinder Singh, PharmD	Health System Pharmacy (SCVMC)	Y
Ali Alkoraishi, MD	Adult & Child Psychiatry	Y
Dolly Goel, MD	VHP Chief Medical Officer	N
Xuan Cung, PharmD	VHP Pharmacy Supervisor	Y
Laurie Nakahira, DO	SCFHP Chief Medical Officer	Y
Dang Huynh, PharmD	SCFHP Pharmacy Director	Y

Non-Voting Committee Members	Specialty	Present (Y or N)
Tami Otomo, PharmD	SCFHP Clinical Pharmacist	Y
Michelle Huynh	SCFHP Pharmacy Coordinator	Y
Duyen Nguyen, PharmD	SCFHP Clinical Pharmacist	Y
Amy McCarty, PharmD	MedImpact	Y
Darryl Breakbill	SCFHP Appeals & Grievance Director	Y
Nancy Aguirre	SCFHP Administrative Assistant	Y
Kelsey Kaku, PharmD	VMC Pharmacy Resident (PGY-2)	Y

1. Introduction

Jimmy Lin, Chair, called the meeting to order at 6:08 pm. Roll call was taken. Missing one committee member to reach a quorum. Meeting commenced while pending the arrival of Dr. Alkoraishi.

2. Public Comment

There were no public comments.

3. Meeting Minutes

The review of the March 21st, 2019 Pharmacy and Therapeutics Committee meeting minutes were tabled. Pending the arrival of Dr. Alkoraishi.

4. Standing Agenda Items

a. CMO Health Plan Updates

Dr. Nakahira announced Dang Huynh as the new Santa Clara Family Health Plan (SCFHP) Pharmacy Director.

Dr. Nakahira noted SCFHP was in the middle of the DHCS & DMHC audit during the last Pharmacy and Therapeutics Committee meeting in March, 2019. Since then, SCFHP has received a draft audit report from DHCS and the Plan is currently responding to their findings. DMHC has yet to submit a report. Anticipating a report to be submitted by early July, 2019.

b. SCFHP/DHCS Global DUR

Dr. Otomo presented the updates on the Plan's global drug utilization review (DUR) programs:

i. Anticholinergic Initiative:

This is a retrospective DUR program specifically looking at Medi-Cal members ages 65 and older with use of second-generation antipsychotic and anticholinergic medication.

Data revealed a total of two (2) members met the criteria. The data showed that each member had one provider for both the anticholinergic medication and the antipsychotic medication. Since there were only two impacted providers, it was the committee's opinion during the last P&T Committee meeting to conduct a direct telephonic outreach to each provider rather than a mailing.

The two impacted providers were cautioned of the potential risks of concomitant of these drug classes. Both providers were aware of these risks and attested that the members are stable on therapy.

In conclusion, in SCFHP's Medi-Cal population of members 65 years and older, benzotropine or trihexyphenidyl and a second-generation antipsychotic, does not appear to be commonly co-prescribed, which is good.

Dr. Ali Alkoraishi arrived at 6:21pm. A quorum was establish at this time. Review of the Pharmacy & Therapeutics Committee meeting minutes of the March 21st, 2019 meeting commenced.

Dr. Lin motioned to accept the meeting minutes as presented. It was motioned by Dr. Nakahira and seconded by Dr. Alkoraishi. The motion carried.

c. Appeals & Grievance

Mr. Breakbill presented the following Appeals & Grievance reports:

i. 2018 4th Quarter Report:

Pharmacy appeals were 50% overturned and 37% were upheld, with 6% partially favorable. Partly favorable is when a prescriber will ask for beyond what is recommended.

ii. 2019 1st Quarter Report:

Format was changed to reflect total amount rather than percentage. Data reveals 19 of the pharmacy appeals for Medi-Cal were overturned, 50 of them were upheld, and 1 was partially favorable. For Cal Medi-Connect, 16 were overturned and 18 were upheld.

d. Emergency Supply Report

Dr. Nguyen presented the Emergency Supply Report. Dr. Nguyen explained the goal of the report is to evaluate access to medications prescribed after emergency room (ER) visits and to determine (if) any barriers to care exists.

i. 2018 2nd Quarter Report:

Evaluated patients diagnosed with urinary tract infections (UTI) and if they were prescribed medications within 72 hours of their ER visit.

There were no issues for approved or denied claims. Denied claims were a result of patient's primary insurance being outside of the Health Plan. For members who did not have a claim (18 members), data revealed most of these patients had a prescription filled several days before, or more than 4 days after their ER visit.

ii. 2018 3rd Quarter Report:

There were no issues identified for approved or denied claims. For members who did not have claim, data revealed the same results for 2018's 2nd quarter report.

Adjourned to Closed Session

Pursuant to Welfare and Institutions Code Section 14087.36 (w)

5. Closed Meeting Minutes

Previous quarter's closed meeting minutes approved.

6. Metrics & Financial Updates

Dr. Nakahira presented the membership reports. Dr. Otomo presented the pharmacy dashboard.

Dr. McCarty presented the Drug Use Evaluation (DUE). Dr. McCarty presented the drug utilization & spend.

7. Discussion and Recommendations for Changes to SCFHP Cal MediConnect (CMC) Formulary & Coverage Determination Criteria

Dr. McCarty presented MedImpact minutes and Part D actions. Both were approved.

8. Discussion and Recommendations for Changes to SCFHP Medi-Cal & Health Kids Formulary & Prior Authorization (PA) Criteria

Dr. Otomo presented formulary modifications and were approved. Dr. McCarty presented CDL updates from February-May 2019 and were approved. Dr. Nguyen presented the PA criteria changes and were approved. Annual PA criteria were reviewed by committee and approved.

9. New Drugs and Class Reviews

Dr. McCarty presented new drugs and class reviews. Recommendations were approved.

Reconvene to Open Session

Committee reconvened to open session at 7:40pm

10. Discussion Items

New and Generic Pipeline

Dr. McCarty presented the new and generic pipeline.


In May, 2019, AVXS-101 came to market with Zolgensma, a gene therapy for Spinal Muscular Atrophy. Cost is high but results are promising. Study included 15 children. 13 out of 15 children responded significantly.

Oral semaglutide (diabetes)-C will come to market in September 2019. First oral treatment in its class. Other treatments are injectable. Anticipating a big impact in utilization when oral semaglutide comes to market.

11. Adjournment

Next meeting is Thursday, September 19th, 2019.

The meeting was adjourned at 7:48pm.



Jimmy Lin, MD
Chair of Pharmacy & Therapeutics Committee

9/19/19
Date